<DOC>
	<DOCNO>NCT02676869</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability recommend phase 2 dose new drug , know IMP321 , combination pembrolizumab give patient unresectable metastatic melanoma .</brief_summary>
	<brief_title>Phase 1 Study IMP321 Adjuvant Anti-PD-1 Therapy Unresectable Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion Criteria 1 . Able give write informed consent comply protocol 2 . Histologically confirm diagnosis locally advance ( unresectable Stage III ) metastatic ( Stage IV ) melanoma 3 . Currently receive antiPD1 therapy pembrolizumab 3 cycle achieve asymptomatic irPD ( slowly progressive , require urgent intervention , stable performance status ) suboptimal response ( irSD , irPR ) demonstrate image assessment perform within 6 week prior day 1 cycle 5 pembrolizumab . 4 . Female male 18 year age 5 . All patient reproductive potential must agree use effective contraception time study entry least 4 month last administration study treatment . 6 . ECOG performance status 01 7 . Expected survival longer three month 8 . Resolution toxicity associate prior current therapy grade &lt; 2 ( except alopecia transaminase case liver metastasis ) 9 . Evidence measurable disease define Response Evaluation Criteria Solid Tumours ( RECIST ) version 1.1 10 . Laboratory criterion : Absolute neutrophil count &gt; 1.5 x 109/L Platelet count ≥ 100 x 109/L Haemoglobin &gt; 9 g/dL 5.58 mmol/L Serum creatinine ≤ 1.5 × ULN Total bilirubin &lt; 20 mmol/L , except familial cholemia ( Gilbert 's disease ) Serum AST ( =GOT ) ALT ( =GPT ) &lt; 3 time upper limit normal &lt; 5 time upper limit normal liver metastasis present Exclusion Criteria 1 . More four prior line therapy advance metastatic disease . 2 . Prior PD1/PDL1 target therapy 3 . Prior highdose chemotherapy require hematopoietic stem cell rescue 4 . Currently receive treatment another investigational drug , less 4 week since end treatment another investigational drug 5 . Currently receive systemic chemotherapy , target small molecule therapy , radiotherapy , biological cancer therapy ( pembrolizumab ) less 4 week since completion therapy first dose study treatment 6 . History irAEs ipilimumab CTCAE Grade 4 require steroid treatment 7 . Known cerebral leptomeningeal metastasis . ( Some subject previously treat brain metastasis may participate specific circumstance ) 8 . Women pregnant lactate 9 . Serious intercurrent infection within 4 week prior first dose study treatment 10 . Evidence severe uncontrolled cardiac disease ( NYHA IIIIV ) within 6 month prior first dose study treatment 11 . Active acute chronic infection 12 . History evidence interstitial lung disease active noninfectious pneumonitis 13 . Active autoimmune disease require immunosuppressive therapy 14 . HIV positivity 15 . Active hepatitis B hepatitis C , currently treat antiviral therapy 16 . Life threaten illness unrelated cancer 17 . Previous malignancy within last three year melanoma 18 . Any current disorder would impede patient 's ability provide inform consent comply protocol 19 . Continuous systemic treatment either corticosteroid immunosuppressive medication within 4 week prior first dose study treatment 20 . History evidence severe allergic episode and/or angioedema 21 . Any current disorder likely modify absorption , distribution elimination IMP321 22 . Alcohol substance abuse disorder 23 . Known hypersensitivity component IMP321 24 . Unwilling unable follow protocol requirement 25 . In clinical judgment investigator , patient unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>